###begin article-title 0
Cardiac 12/15 lipoxygenase-induced inflammation is involved in heart failure
###end article-title 0
###begin p 1
Y. Kayama, T. Minamino, and H. Toko contributed equally to this paper.
###end p 1
###begin p 2
###xml 139 145 139 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 421 427 421 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 506 512 506 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 726 732 726 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 1104 1110 1104 1110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 328 343 <span type="species:ncbi:10090">transgenic mice</span>
###xml 428 443 <span type="species:ncbi:10090">transgenic mice</span>
###xml 513 528 <span type="species:ncbi:10090">transgenic mice</span>
###xml 733 748 <span type="species:ncbi:10090">transgenic mice</span>
###xml 773 777 <span type="species:ncbi:10090">mice</span>
###xml 1111 1126 <span type="species:ncbi:10090">transgenic mice</span>
To identify a novel target for the treatment of heart failure, we examined gene expression in the failing heart. Among the genes analyzed, Alox15 encoding the protein 12/15 lipoxygenase (LOX) was markedly up-regulated in heart failure. To determine whether increased expression of 12/15-LOX causes heart failure, we established transgenic mice that overexpressed 12/15-LOX in cardiomyocytes. Echocardiography showed that Alox15 transgenic mice developed systolic dysfunction. Cardiac fibrosis increased in Alox15 transgenic mice with advancing age and was associated with the infiltration of macrophages. Consistent with these observations, cardiac expression of monocyte chemoattractant protein 1 (MCP-1) was up-regulated in Alox15 transgenic mice compared with wild-type mice. Treatment with 12-hydroxy-eicosatetraenoic acid, a major metabolite of 12/15-LOX, increased MCP-1 expression in cardiac fibroblasts and endothelial cells but not in cardiomyocytes. Inhibition of MCP-1 reduced the infiltration of macrophages into the myocardium and prevented both systolic dysfunction and cardiac fibrosis in Alox15 transgenic mice. Likewise, disruption of 12/15-LOX significantly reduced cardiac MCP-1 expression and macrophage infiltration, thereby improving systolic dysfunction induced by chronic pressure overload. Our results suggest that cardiac 12/15-LOX is involved in the development of heart failure and that inhibition of 12/15-LOX could be a novel treatment for this condition.
###end p 2
###begin p 3
###xml 141 166 141 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib27">Libby and Braunwald, 2008</xref>
###xml 534 554 531 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">Garg and Yusuf, 1995</xref>
###xml 556 570 553 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib29">McMurray, 1999</xref>
###xml 572 587 569 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">Goldstein, 2002</xref>
###xml 668 693 665 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib27">Libby and Braunwald, 2008</xref>
###xml 505 513 <span type="species:ncbi:9606">patients</span>
Heart failure is a clinical syndrome that is associated with various cardiovascular diseases such as hypertension and myocardial infarction (Libby and Braunwald, 2008). Comprehensive management using current therapeutic options can markedly reduce the morbidity and mortality of heart failure. Large-scale clinical trials of drugs targeting neurohormonal mechanisms, such as angiotensin-converting enzyme inhibitors and beta blockers, have shown that such treatment is effective for reducing mortality in patients with heart failure (Garg and Yusuf, 1995; McMurray, 1999; Goldstein, 2002). However, heart failure is still one of the leading causes of death worldwide (Libby and Braunwald, 2008), so it is important to investigate the underlying mechanisms of this condition and develop more effective treatments.
###end p 3
###begin p 4
###xml 276 299 276 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">Kudo and Murakami, 2002</xref>
###xml 455 479 455 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">Kuhn and O'Donnell, 2006</xref>
###xml 708 725 708 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">Chen et al., 1994</xref>
###xml 787 808 787 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib40">Yokoyama et al., 1986</xref>
###xml 928 952 928 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">Kuhn and O'Donnell, 2006</xref>
###xml 1118 1144 1118 1144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib32">Natarajan and Nadler, 2004</xref>
###xml 1146 1170 1146 1170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">Kuhn and O'Donnell, 2006</xref>
###xml 1283 1301 1283 1301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">Cyrus et al., 1999</xref>
###xml 1303 1307 1303 1307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">2001</xref>
###xml 1309 1328 1309 1328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16">George et al., 2001</xref>
###xml 1459 1478 1459 1478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">Hatley et al., 2003</xref>
###xml 1480 1499 1480 1499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib34">Reilly et al., 2004</xref>
###xml 1501 1520 1501 1520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">Bolick et al., 2005</xref>
###xml 1638 1658 1638 1658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">McNally et al., 1990</xref>
###xml 1660 1682 1660 1682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib35">Sakashita et al., 1999</xref>
###xml 1684 1701 1684 1701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib42">Zhu et al., 2003b</xref>
###xml 1844 1864 1844 1864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib31">Nagelin et al., 2008</xref>
###xml 1985 2004 1985 2004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">Bleich et al., 1999</xref>
###xml 2031 2052 2031 2052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib28">McDuffie et al., 2008</xref>
###xml 1226 1230 <span type="species:ncbi:10090">mice</span>
###xml 1378 1382 <span type="species:ncbi:10090">mice</span>
###xml 1882 1886 <span type="species:ncbi:10090">mice</span>
Arachidonic acid is a free fatty acid that, when liberated from cell membranes, can be metabolized by cyclooxygenase, cytochrome p450, and lipoxygenase (LOX) to form biologically active products such as prostaglandins, leukotrienes, and hydroxy-eicosatetraenoic acids (HETEs; Kudo and Murakami, 2002). LOXs are a family of lipid-peroxidizing enzymes that oxidize free and esterified polyenolic fatty acids to form the corresponding hydroperoxy derivates (Kuhn and O'Donnell, 2006). The LOX enzymes are named according to the specific carbon atoms of arachidonic acid that are oxidized. Thus, 12/15-LOX is a member of the LOX family that catalyzes the step from arachidonic acid to 12(S)-HETE and 15(S)-HETE (Chen et al., 1994). 12/15-LOX was originally isolated from porcine leukocytes (Yokoyama et al., 1986), but its tissue distribution is now known to be relatively wide, including blood vessels, the brain, and the kidneys (Kuhn and O'Donnell, 2006). Several lines of evidence have suggested that 12/15-LOX may play an important role in the development of atherosclerosis, diabetes, and neurodegenerative disease (Natarajan and Nadler, 2004; Kuhn and O'Donnell, 2006). For example, disruption of the gene for 12/15-LOX in mice significantly reduces the onset of atherosclerosis (Cyrus et al., 1999, 2001; George et al., 2001), whereas an increase of 12/15-LOX expression in mice promotes monocyte-endothelial cell interactions that lead to atherogenesis (Hatley et al., 2003; Reilly et al., 2004; Bolick et al., 2005). Several studies have shown that monocyte 12/15-LOX mediates the oxidative modification of low-density lipoprotein (McNally et al., 1990; Sakashita et al., 1999; Zhu et al., 2003b). An increase of 12/15-LOX activity in vessel walls also contributes to atherogenesis by impairing the macrophage cholesterol efflux pathway (Nagelin et al., 2008). Interestingly, mice with deficiency of 12/15-LOX are resistant to the development of streptozotocin-induced diabetes (Bleich et al., 1999) and autoimmune diabetes (McDuffie et al., 2008). However, there is currently little evidence that 12/15-LOX has a role in heart failure.
###end p 4
###begin p 5
###xml 429 435 429 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
In the present study, we showed that cardiac 12/15-LOX induces inflammation that is involved in heart failure. We found that 12/15-LOX expression was markedly increased in the failing heart. Increased expression of this enzyme up-regulates monocyte chemoattractant protein 1 (MCP-1) and promotes the infiltration of macrophages into the heart, thereby causing cardiac fibrosis and systolic dysfunction. Conversely, disruption of Alox15 reduces cardiac MCP-1 expression and macrophage infiltration, thereby improving systolic dysfunction induced by chronic pressure overload. These findings suggest that inhibition of 12/15-LOX could be a novel treatment for heart failure.
###end p 5
###begin title 6
RESULTS
###end title 6
###begin title 7
Increased expression of 12/15-LOX causes heart failure
###end title 7
###begin p 8
###xml 543 549 540 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 660 668 657 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 A</xref>
###xml 790 798 787 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 B</xref>
###xml 925 933 922 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 C</xref>
###xml 186 190 <span type="species:ncbi:10116">rats</span>
To clarify the molecular mechanisms of heart failure, we performed microarray analysis using cardiac tissue samples obtained from a hypertensive heart failure model (Dahl salt-sensitive rats). Approximately 300 genes showed significant changes of expression in failing hearts compared with control hearts. For example, fetal genes, such as the natriuretic peptide genes and the beta-type myosin heavy chain gene, were up-regulated, whereas cardioprotective genes, such as heat shock proteins, were down-regulated (). Among the genes analyzed, Alox15 encoding the protein 12/15-LOX was most markedly up-regulated in failing hearts compared with control hearts (Fig. 1 A). Northern blot analysis confirmed that the messenger RNA (mRNA) for this gene was strikingly elevated in heart failure (Fig. 1 B). Immunohistochemistry showed that expression of 12/15-LOX was specifically up-regulated in cardiomyocytes of failing hearts (Fig. 1 C).
###end p 8
###begin p 9
###xml 0 61 0 61 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Expression of 12/15-LOX is up-regulated in the failing heart.</bold>
###xml 480 486 480 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 642 648 642 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 86 90 <span type="species:ncbi:10116">rats</span>
###xml 338 342 <span type="species:ncbi:10116">Rats</span>
###xml 928 934 <span type="species:ncbi:9986">rabbit</span>
Expression of 12/15-LOX is up-regulated in the failing heart. (A) Dahl salt-sensitive rats were fed a low-sodium diet until the age of 6 wk and then a high-sodium diet (8% NaCl) throughout the experimental period. In this model, prominent cardiac hypertrophy developed and left ventricular systolic function was impaired by 17 wk of age. Rats fed a low-salt diet (0.3% NaCl) served as the control. The animals were sacrificed for gene chip analysis at 17 wk of age. Expression of Alox15 was markedly up-regulated in failing hearts (HF) compared with control hearts (Cont). (B) Northern blot analysis confirmed that the expression of mRNA for Alox15 was strikingly elevated in failing hearts. (C) Immunohistochemistry for 12/15-LOX in the heart at 17 wk of age. Expression of 12/15-LOX (red) was specifically up-regulated in cardiomyocytes (green) of failing hearts. Nuclei were stained with DAPI (blue). Bars, 20 microm. Normal rabbit serum was used as a negative control of polyclonal antibody against 12/15-LOX. Results in A are obtained from one experiment. Results in B and C are representative of three independent experiments.
###end p 9
###begin p 10
###xml 97 103 97 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 154 160 154 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 412 420 396 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 A</xref>
###xml 547 555 531 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 B</xref>
###xml 671 677 655 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 695 703 679 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 C</xref>
###xml 833 839 817 823 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 910 918 894 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 D</xref>
###xml 1009 1017 993 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 D</xref>
###xml 1093 1099 1077 1083 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 1227 1242 1211 1226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2, E and F</xref>
###xml 1295 1301 1279 1285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 1439 1445 1423 1429 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 104 119 <span type="species:ncbi:10090">transgenic mice</span>
###xml 147 153 <span type="species:ncbi:10090">murine</span>
###xml 263 278 <span type="species:ncbi:10090">transgenic mice</span>
###xml 478 493 <span type="species:ncbi:10090">transgenic mice</span>
###xml 678 693 <span type="species:ncbi:10090">transgenic mice</span>
###xml 840 855 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1100 1115 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1302 1317 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1446 1461 <span type="species:ncbi:10090">transgenic mice</span>
To determine whether increased expression of 12/15-LOX could cause heart failure, we established Alox15 transgenic mice in which expression of the murine Alox15 gene was under the control of the alpha-cardiac myosin heavy chain promoter. We obtained two lines of transgenic mice, both of which showed an approximately10-fold increase in the myocardial expression of 12/15-LOX compared with their WT littermates (Fig. 2 A; and ). Histological examination also indicated that the transgenic mice showed increased myocardial expression of 12/15-LOX (Fig. 2 B and Fig. S1 C). Consequently, production of 12(S)-HETE and 15(S)-HETE was significantly increased in the hearts of Alox15 transgenic mice (Fig. 2 C). The left ventricular diastolic dimension (LVDd) was increased and left ventricular fractional shortening (FS) was decreased in Alox15 transgenic mice from 26 wk of age compared with their WT littermates (Fig. 2 D). These changes observed in the transgenic animals showed further progression with aging (Fig. 2 D). Histological examination revealed that cardiac fibrosis was increased in Alox15 transgenic mice and that this fibrosis also progressed with advancing age and was associated with infiltration of macrophages (Fig. 2, E and F). There was no difference in blood pressure between Alox15 transgenic mice and their WT littermates at 16 or 48 wk of age (Fig. S1 D). The cardiac changes were similar in two independent lines of Alox15 transgenic mice, suggesting that increased expression of 12/15-LOX might cause heart failure by inducing myocardial inflammation.
###end p 10
###begin p 11
###xml 0 55 0 55 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Increased expression of 12/15-LOX causes heart failure.</bold>
###xml 130 136 130 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 295 301 295 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 495 501 491 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 641 647 637 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 900 901 894 895 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 910 911 904 905 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1115 1121 1109 1115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 1610 1611 1593 1594 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 153 157 <span type="species:ncbi:10090">mice</span>
###xml 302 317 <span type="species:ncbi:10090">transgenic mice</span>
###xml 502 517 <span type="species:ncbi:10090">transgenic mice</span>
###xml 560 575 <span type="species:ncbi:10090">transgenic mice</span>
###xml 648 663 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1021 1036 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1122 1137 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1381 1396 <span type="species:ncbi:10090">transgenic mice</span>
Increased expression of 12/15-LOX causes heart failure. (A) Western blot analysis of 12/15-LOX expression in the hearts of WT and Alox15 transgenic (Tg) mice using anti-12/15-LOX antibody (12/15-LOX) or anti-HA antibody (HA). (B) Immunohistochemistry for 12/15-LOX (red) in the hearts of WT and Alox15 transgenic mice. Nuclei were stained with DAPI (blue). Bars, 40 microm. Results in A and B are representative of three independent experiments. (C) 12/15(S)-HETE levels in the hearts of WT and Alox15 transgenic mice. (D) Echocardiographic findings in WT and transgenic mice. The LVDd was increased and left ventricular FS was decreased in Alox15 transgenic mice compared with their WT littermates. These changes observed in the transgenic animals showed progression with aging. *, P < 0.05; **, P < 0.01 versus WT. Results in C and D represent the mean +/- SEM of three independent experiments. C, n = 6; D, n = 14. (E) Masson trichrome staining (top) and immunohistochemistry for Mac3 (bottom) in the hearts of WT and transgenic mice at the ages of 16 wk (16w) and 48 wk (48w). Cardiac fibrosis was increased in Alox15 transgenic mice, and this fibrosis progressed with advancing age and was associated with infiltration of macrophages. Bars, 100 microm. Results are representative of three independent experiments. (F) The number of Mac3-positive cells in the hearts of WT and transgenic mice at the ages of 16 wk (16w) and 48 wk (48w). *, P < 0.01 versus WT (16w); #, P < 0.01 versus WT (48w); dagger, P < 0.01 versus transgenic (16w). Results represent the mean +/- SEM of three independent experiments; n = 7.
###end p 11
###begin title 12
12/15-LOX induces cardiac inflammation
###end title 12
###begin p 13
###xml 91 97 91 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 304 308 304 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ccl2</italic>
###xml 348 354 348 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 394 402 394 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 A</xref>
###xml 480 484 480 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ccl2</italic>
###xml 542 557 542 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3, B and C</xref>
###xml 638 646 638 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 D</xref>
###xml 861 869 857 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 E</xref>
###xml 1031 1039 1023 1031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 E</xref>
###xml 98 113 <span type="species:ncbi:10090">transgenic mice</span>
###xml 355 370 <span type="species:ncbi:10090">transgenic mice</span>
###xml 388 392 <span type="species:ncbi:10090">mice</span>
To investigate the mechanism by which cardiac infiltration of macrophages was increased in Alox15 transgenic mice, we examined the expression of various proinflammatory cytokines that are thought to be macrophage chemoattractants by the ribonuclease protection assay. We found that cardiac expression of Ccl2 (MCP-1) was significantly increased in Alox15 transgenic mice compared with WT mice (Fig. 3 A). In vitro experiments demonstrated that treatment with 12(S)-HETE increased Ccl2 expression by cardiac fibroblasts and endothelial cells (Fig. 3, B and C), whereas there was no effect when cardiomyocytes were treated with 12(S)-HETE (Fig. 3 D). Moreover, incubation of COS7 cells with 12(S)-HETE significantly increased the activity of nuclear factor kappaB, a transcription factor that regulates the induction of proinflammatory cytokines including MCP-1 (Fig. 3 E). In contrast, 12(S)-HETE did not affect the activity of this factor when cells were transfected with a reporter plasmid containing mutant kappaB binding sites (Fig. 3 E). These results suggest that increased production of 12(S)-HETE by cardiomyocytes causes up-regulation of MCP-1 in other cells of the heart, thereby leading to accumulation of macrophages.
###end p 13
###begin p 14
###xml 0 40 0 40 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12/15-LOX up-regulates MCP-1 expression.</bold>
###xml 59 63 59 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ccl2</italic>
###xml 109 118 109 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12/15-LOX</italic>
###xml 221 225 221 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ccl2</italic>
###xml 249 253 249 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ccl2</italic>
###xml 283 289 283 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 415 416 413 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 523 525 521 523 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 591 595 589 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ccl2</italic>
###xml 685 689 683 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ccl2</italic>
###xml 728 732 726 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ccl2</italic>
###xml 881 882 877 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 900 901 896 897 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1078 1080 1070 1072 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 1446 1447 1424 1425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 135 139 <span type="species:ncbi:10090">mice</span>
###xml 290 305 <span type="species:ncbi:10090">transgenic mice</span>
###xml 317 321 <span type="species:ncbi:10090">mice</span>
12/15-LOX up-regulates MCP-1 expression. (A) Expression of Ccl2 (MCP-1) was examined in the hearts of WT and 12/15-LOX transgenic (Tg) mice by the ribonuclease protection assay. The graph indicates relative expression of Ccl2. Cardiac expression of Ccl2 was significantly greater in Alox15 transgenic mice than in WT mice. *, P < 0.05 versus WT. Results represent the mean +/- SEM of three independent experiments; n = 6. (B-D) Cardiac fibroblasts (B), endothelial cells (C), and cardiomyocytes (D) were treated with 5 x 10-7 M 12(S)-HETE for the indicated times (0-24 h), and expression of Ccl2 was examined by the ribonuclease protection assay. Graphs display relative expression of Ccl2. Incubation with 12(S)-HETE increased Ccl2 expression by cardiac fibroblasts and endothelial cells. *, P < 0.01 versus time 0. Results represent mean +/- SEM of four independent experiments; n = 4 for B and C; n = 7 for D. (E) The luciferase reporter gene plasmid containing the kappaB binding site was transfected into COS7 cells, which were cultured in the absence or presence of 5 x 10-7 M 12(S)-HETE. The luciferase assay was performed 12 h later. A reporter plasmid containing the mutant kappaB binding site was used as the negative control. Incubation of cells with 12(S)-HETE significantly increased the activity of nuclear factor kappaB. *, P < 0.01 versus 12(S)-HETE (-)/kappaB. Results represent the mean +/- SEM of five independent experiments; n = 6.
###end p 14
###begin p 15
###xml 151 157 151 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 290 304 290 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">Egashira, 2003</xref>
###xml 496 504 496 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 A</xref>
###xml 616 630 616 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">Egashira, 2003</xref>
###xml 777 792 777 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">Ni et al., 2001</xref>
###xml 866 890 866 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">Hayashidani et al., 2003</xref>
###xml 1070 1076 1070 1076 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 1170 1185 1170 1185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4, B and C</xref>
###xml 158 173 <span type="species:ncbi:10090">transgenic mice</span>
###xml 224 229 <span type="species:ncbi:9606">human</span>
###xml 359 363 <span type="species:ncbi:10090">mice</span>
###xml 483 488 <span type="species:ncbi:9606">human</span>
###xml 1077 1092 <span type="species:ncbi:10090">transgenic mice</span>
To investigate the relationship between up-regulation of MCP-1 and heart failure, we examined the effect of MCP-1 inhibition on cardiac dysfunction in Alox15 transgenic mice. We injected an expression vector encoding mutant human MCP-1 with deletion of N-terminal amino acids (7ND plasmid; Egashira, 2003) or the empty vector (mock) into the thigh muscles of mice every 2 wk until 48 wk of age. The result was a significant increase in the blood level of 7ND and elevation of plasma human MCP-1 (Fig. 4 A and ). This mutant MCP-1 binds to the MCP-1 receptor (chemokine receptor 2) and inhibits downstream signaling (Egashira, 2003). Consequently, injection of the 7ND plasmid has been reported to suppress MCP-1 activity in vivo and inhibit the development of atherosclerosis (Ni et al., 2001), as well as inhibiting cardiac remodelling after myocardial infarction (Hayashidani et al., 2003). In agreement with these results, histological examination and echocardiography demonstrated that injection of this plasmid reduced the myocardial infiltration of macrophages in Alox15 transgenic mice, as well as preventing systolic dysfunction and left ventricular dilatation (Fig. 4, B and C). These results suggested that 12/15-LOX induces cardiac dysfunction by up-regulation of MCP-1 expression in the heart.
###end p 15
###begin p 16
###xml 52 58 52 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 0 78 0 78 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Inhibition of MCP-1 prevents cardiac dysfunction in <italic>Alox15</italic> transgenic animals.</bold>
###xml 453 454 451 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 674 680 672 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 902 908 900 906 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 1076 1077 1072 1073 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1086 1087 1082 1083 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 109 114 <span type="species:ncbi:9606">human</span>
###xml 126 132 <span type="species:ncbi:10090">murine</span>
###xml 256 261 <span type="species:ncbi:9606">human</span>
###xml 514 518 <span type="species:ncbi:10090">mice</span>
###xml 536 540 <span type="species:ncbi:10090">mice</span>
###xml 546 561 <span type="species:ncbi:10090">transgenic mice</span>
###xml 681 696 <span type="species:ncbi:10090">transgenic mice</span>
###xml 735 739 <span type="species:ncbi:10090">mice</span>
###xml 741 756 <span type="species:ncbi:10090">transgenic mice</span>
###xml 762 777 <span type="species:ncbi:10090">transgenic mice</span>
###xml 909 924 <span type="species:ncbi:10090">transgenic mice</span>
Inhibition of MCP-1 prevents cardiac dysfunction in Alox15 transgenic animals. (A) The plasma levels of 7ND (human MCP-1) and murine MCP-1 were determined by ELISA at the indicated times after introduction of the 7ND expression vector. The plasma level of human MCP-1 was significantly increased after injection of the 7ND plasmid. *, P < 0.01 versus day 0; #, P < 0.01 versus day 3. Results represent the mean +/- SEM of three independent experiments; n = 5. (B) Number of Mac3-positive cells in the hearts of WT mice, transgenic (Tg) mice, and transgenic mice treated with 7ND (Tg + 7ND). Injection of the 7ND plasmid reduced the myocardial infiltration of macrophages in Alox15 transgenic mice. (C) Echocardiographic findings in WT mice, transgenic mice, and transgenic mice treated with 7ND (Tg + 7ND). Injection of the 7ND plasmid prevented systolic dysfunction and left ventricular dilatation in Alox15 transgenic mice. *, P < 0.05; **, P < 0.01 versus WT; #, P < 0.05; ##, P < 0.01 versus transgenic. Results represent mean +/- SEM of three independent experiments. B, n = 7; C, n = 10-14.
###end p 16
###begin title 17
Cardiac expression of 12/15-LOX is up-regulated during pressure overload
###end title 17
###begin p 18
###xml 406 414 406 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 A</xref>
###xml 439 445 439 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 488 496 488 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 B</xref>
###xml 580 588 580 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 C</xref>
###xml 701 709 701 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 A</xref>
###xml 104 108 <span type="species:ncbi:10090">mice</span>
To further investigate the role of 12/15-LOX in heart failure, we examined its cardiac expression in WT mice with severe transverse aortic constriction (TAC). In this model, cardiac hypertrophy gradually progresses to reach a peak on day 7 after TAC and then decreases afterward (not depicted). FS was preserved until day 7 but was significantly decreased on day 14 along with left ventricular dilatation (Fig. 5 A). Cardiac expression of Alox15 was significantly up-regulated after TAC (Fig. 5 B), and the production of both 12(S)-HETE and 15(S)-HETE was increased in the heart (Fig. 5 C). Histological examination demonstrated an increase in the expression of 12/15-LOX by cardiomyocytes after TAC (Fig. 6 A and ).
###end p 18
###begin p 19
###xml 0 73 0 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cardiac expression of 12/15-LOX is up-regulated during pressure overload.</bold>
###xml 115 121 115 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 328 334 328 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 659 660 657 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 677 683 675 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 1129 1130 1125 1126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 137 141 <span type="species:ncbi:10090">mice</span>
###xml 308 312 <span type="species:ncbi:10090">mice</span>
###xml 765 769 <span type="species:ncbi:10090">mice</span>
Cardiac expression of 12/15-LOX is up-regulated during pressure overload. (A) Echocardiographic findings in WT and Alox15-deficient (KO) mice on day 7 (D7) and day 14 (D14) after TAC surgery. FS was preserved until day 7 but was significantly decreased on day 14 along with left ventricular dilatation in WT mice. Disruption of Alox15 (KO) significantly improved systolic dysfunction and prevented left ventricular dilatation caused by chronic pressure overload. LVDs, left ventricular systolic dimension; sham, sham operation. *, P < 0.01 versus sham; #, P < 0.05; ##, P < 0.01 versus WT. Results represent the mean +/- SEM of three independent experiments; n = 10. (B and C) Alox15 expression (B) and the 12/15(S)-HETE level (C) were examined in the hearts of WT mice on day 7 (D7) and day 14 (D14) after TAC surgery by real-time PCR and ELISA, respectively. Cardiac expression of 12/15-LOX was significantly up-regulated after TAC, and production of both 12(S)-HETE and 15(S)-HETE was increased in the heart. *, P < 0.01 versus sham; #, P < 0.01 versus D7. Results represent the mean +/- SEM of three independent experiments; n = 6.
###end p 19
###begin p 20
###xml 14 20 14 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 0 78 0 78 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Disruption of <italic>Alox15</italic> attenuates cardiac inflammation during pressure overload.</bold>
###xml 226 232 226 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 548 554 544 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 692 698 688 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 844 845 838 839 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 871 875 865 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ccl2</italic>
###xml 888 892 882 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cd68</italic>
###xml 930 936 924 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 1134 1140 1128 1134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 1266 1267 1258 1259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 179 183 <span type="species:ncbi:10090">mice</span>
###xml 198 202 <span type="species:ncbi:10090">mice</span>
###xml 243 247 <span type="species:ncbi:10090">mice</span>
###xml 348 352 <span type="species:ncbi:10090">mice</span>
###xml 364 368 <span type="species:ncbi:10090">mice</span>
###xml 570 574 <span type="species:ncbi:10090">mice</span>
###xml 709 713 <span type="species:ncbi:10090">mice</span>
###xml 715 717 <span type="species:ncbi:10090">KO</span>
###xml 948 950 <span type="species:ncbi:10090">KO</span>
###xml 952 956 <span type="species:ncbi:10090">mice</span>
Disruption of Alox15 attenuates cardiac inflammation during pressure overload. (A) Double immunostaining for 12/15-LOX (red) and actinin (green) in the hearts of sham-operated WT mice (WT sham), WT mice with TAC (WT TAC), and Alox15-deficient mice with TAC (KO TAC). Increased expression of 12/15-LOX was observed in cardiomyocytes after TAC in WT mice but not KO mice. Nuclei were stained with DAPI (blue). Bars, 20 microm. Results are representative of four independent experiments. (B) 12/15(S)-HETE levels were examined in the hearts of WT and Alox15-deficient (KO) mice after sham surgery or TAC. The increase of 12(S)-HETE and 15(S)-HETE production after TAC was markedly attenuated in Alox15-deficient mice (KO). *, P < 0.01 versus WT sham; #, P < 0.01 versus WT TAC. Results represent the mean +/- SEM of three independent experiments; n = 6-8. (C) Expression of Ccl2 (MCP-1) and Cd68 was examined in the hearts of WT and Alox15-deficient (KO) mice after sham surgery or TAC. Expression of both genes was increased by about threefold at 14 d after TAC. This increase of expression was significantly inhibited by disruption of Alox15. *, P < 0.01 versus WT sham; #, P < 0.01 versus WT TAC. Results represent the mean +/- SEM of three independent experiments; n = 6-8.
###end p 20
###begin p 21
###xml 16 22 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 185 191 185 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 193 199 193 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6</xref>
###xml 216 222 216 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 397 405 397 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 A</xref>
###xml 542 548 542 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 626 630 626 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ccl2</italic>
###xml 779 783 779 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ccl2</italic>
###xml 788 792 788 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cd68</italic>
###xml 849 855 849 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 857 865 857 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 C</xref>
###xml 33 37 <span type="species:ncbi:10090">mice</span>
###xml 75 79 <span type="species:ncbi:10090">mice</span>
We next created Alox15-deficient mice with TAC and compared them to WT TAC mice. The increase of 12(S)-HETE and 15(S)-HETE production after TAC was markedly attenuated by disruption of Alox15 (Fig. 6). Disruption of Alox15 also significantly improved systolic dysfunction and prevented left ventricular dilatation in the presence of chronic pressure overload without any change of blood pressure (Fig. 5 A and ), indicating that 12/15-LOX has an important role in the induction of cardiac dysfunction by pressure overload. To examine whether Alox15 deficiency could inhibit cardiac inflammation, we assessed the expression of Ccl2 and a macrophage marker (Cd68) in the heart after TAC. Expression of both genes was increased by about threefold at 14 d after TAC. The increase of Ccl2 and Cd68 expression was significantly inhibited by disruption of Alox15 (Fig. 6 C), suggesting that this gene has a crucial role in the development of heart failure by promoting cardiac inflammation.
###end p 21
###begin title 22
DISCUSSION
###end title 22
###begin p 23
###xml 301 320 301 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">Lebeau et al., 2004</xref>
###xml 322 338 322 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">Jin et al., 2008</xref>
###xml 340 359 340 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib37">Seiler et al., 2008</xref>
###xml 546 552 546 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 884 890 884 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 1390 1411 1390 1411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib25">Kuwahara et al., 2004</xref>
###xml 1551 1575 1551 1575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib22">Kolattukudy et al., 1998</xref>
###xml 1742 1763 1742 1763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib25">Kuwahara et al., 2004</xref>
###xml 553 568 <span type="species:ncbi:10090">transgenic mice</span>
###xml 649 653 <span type="species:ncbi:10090">mice</span>
###xml 891 906 <span type="species:ncbi:10090">transgenic mice</span>
We demonstrated a crucial role of 12/15-LOX-induced inflammation in the development of heart failure. Activation of this enzyme has been shown to promote neuronal death, whereas inhibition of 12/15-LOX protects against brain damage caused by oxidative stress or ischemia by inhibiting neuronal death (Lebeau et al., 2004; Jin et al., 2008; Seiler et al., 2008). In contrast, treatment with 12(S)-HETE does not induce the apoptosis of cultured cardiomyocytes (unpublished data). Indeed, few apoptotic cardiomyocytes were detected in the hearts of Alox15 transgenic mice even after the onset of systolic dysfunction (unpublished data). Instead, these mice showed an increase of macrophages infiltrating into the myocardium, which was associated with cardiac fibrosis and systolic dysfunction. Our findings suggested that MCP-1 may have a major role in promoting cardiac inflammation in Alox15 transgenic mice because its inhibition almost completely abolished the accumulation of macrophages and prevented systolic dysfunction. We also showed that 12/15-LOX induces up-regulation of MCP-1 expression in the setting of pressure overload, thereby increasing cardiac inflammation and leading to systolic dysfunction. Consistent with our findings, inhibition of MCP-1 has been reported to attenuate myocardial inflammation, fibrosis, and cardiac dysfunction induced by chronic pressure overload (Kuwahara et al., 2004). It has also been reported that transgenic animals with cardiac expression of MCP-1 develop myocardial fibrosis and systolic dysfunction (Kolattukudy et al., 1998). In agreement with our in vitro data, it has been reported that MCP-1 expression is up-regulated in vascular endothelial cells and fibroblasts by pressure overload (Kuwahara et al., 2004). Collectively, these results indicate that chronic pressure overload increases the expression of 12/15-LOX, which then causes heart failure by promoting cardiac inflammation and fibrosis.
###end p 23
###begin p 24
###xml 736 755 732 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">Bolick et al., 2005</xref>
###xml 757 761 753 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">2006</xref>
###xml 763 779 759 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib38">Wen et al., 2007</xref>
###xml 781 785 777 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib39">2008</xref>
###xml 787 811 783 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">Dwarakanath et al., 2008</xref>
###xml 892 911 884 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">Bolick et al., 2005</xref>
###xml 913 917 905 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">2006</xref>
###xml 919 943 911 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">Dwarakanath et al., 2008</xref>
###xml 1091 1113 1083 1105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">Andersson et al., 2008</xref>
###xml 57 61 <span type="species:ncbi:10090">mice</span>
Target gene disruption or overexpression of 12/15-LOX in mice with a genetic background of apolipoprotein E or low-density lipoprotein receptor deficiency has shown that this enzyme may have a role in atherogenesis. The data indirectly support a role for 12/15-LOX in the oxidative modification of low-density lipoprotein. Consistent with our results, recent evidence suggests that 12/15-LOX plays a crucial role in the regulation of proinflammatory molecules and that this regulatory activity of 12/15-LOX may be important for linking 12/15-LOX activation to atherogenesis. For example, 12(S)-HETE increases the expression of MCP-1, interleukin 6, tumor necrosis factor alpha, and adhesion molecules by macrophages and vascular cells (Bolick et al., 2005, 2006; Wen et al., 2007, 2008; Dwarakanath et al., 2008), and these changes are partly mediated by activation of nuclear factor kappaB (Bolick et al., 2005, 2006; Dwarakanath et al., 2008). Disruption of 12/15-LOX has also been shown to attenuate airway allergic inflammation by modulating the expression of proinflammatory cytokines (Andersson et al., 2008).
###end p 24
###begin p 25
###xml 287 304 287 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib36">Sano et al., 2007</xref>
###xml 626 648 626 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib3">Bernaudin et al., 2002</xref>
###xml 650 667 650 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib41">Zhu et al., 2003a</xref>
###xml 943 949 939 945 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 1041 1065 1037 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">Cummins and Taylor, 2005</xref>
The mechanism of 12/15-LOX activation in the failing heart is unclear. We previously demonstrated that mismatch between the number of capillaries and the size of cardiomyocytes occurs during the development of cardiac hypertrophy, leading to myocardial hypoxia and systolic dysfunction (Sano et al., 2007). Because exposure of cultured cardiomyocytes to hypoxia up-regulates 12/15-LOX expression (unpublished data), a hypoxic state might be one reason for the induction of 12/15-LOX in the failing heart. This concept is supported by previous results that hypoxia up-regulates 12/15-LOX expression in the lungs and the brain (Bernaudin et al., 2002; Zhu et al., 2003a). Moreover, we have found that 12/15-LOX expression is significantly up-regulated in the heart after myocardial infarction (unpublished data). There are putative binding elements for CCAAT/enhancer binding proteins and nuclear factor kappaB within the promoter region of the Alox15 gene (unpublished data), and both of these molecules are known to be activated by hypoxia (Cummins and Taylor, 2005).
###end p 25
###begin p 26
###xml 465 480 461 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">Braunwald, 2008</xref>
###xml 651 669 647 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">Anand et al., 2005</xref>
###xml 870 896 866 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib32">Natarajan and Nadler, 2004</xref>
###xml 898 922 894 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">Kuhn and O'Donnell, 2006</xref>
###xml 380 387 <span type="species:ncbi:9606">persons</span>
###xml 605 613 <span type="species:ncbi:9606">patients</span>
Inflammation has an important role in the pathogenesis and progression of many forms of heart failure, and biomarkers of inflammation have become the subject of intense investigation. In the Framingham Heart Study, an increase of C-reactive protein (as well as inflammatory cytokines such as interleukin 6 and tumor necrosis factor alpha) was found to identify asymptomatic older persons in the community with a high risk of developing heart failure in the future (Braunwald, 2008). Multivariate analysis has shown that an increase of C-reactive protein is an independent predictor of adverse outcomes in patients with acute or chronic heart failure (Anand et al., 2005), suggesting that heart failure is closely associated with systemic inflammation. Because metabolites of 12/15-LOX may have a role in vascular inflammation, insulin resistance, and renal dysfunction (Natarajan and Nadler, 2004; Kuhn and O'Donnell, 2006), activation of 12/15-LOX in the failing heart could induce systemic inflammation and have a detrimental effect on other inflammatory diseases such as atherosclerosis, metabolic syndrome, and nephropathy. Conversely, inhibition of 12/15-LOX could be an attractive new strategy for the treatment of heart failure, as well as various other inflammatory conditions.
###end p 26
###begin title 27
MATERIALS AND METHODS
###end title 27
###begin title 28

###end title 28
###begin title 29
Animal models.
###end title 29
###begin p 30
###xml 112 116 <span type="species:ncbi:10116">rats</span>
###xml 146 150 <span type="species:ncbi:10116">rats</span>
###xml 411 415 <span type="species:ncbi:10116">rats</span>
###xml 479 483 <span type="species:ncbi:10116">rats</span>
###xml 673 677 <span type="species:ncbi:10116">rats</span>
All of the experimental protocols were approved by Chiba University review board. Male Dahl salt-sensitive (DS) rats were purchased from SLC. The rats were fed a low-sodium diet until the age of 6 wk and then a high-sodium diet (8% NaCl) throughout the experimental period. In this model, marked cardiac hypertrophy developed and left ventricular systolic function was impaired at 17 wk of age. Accordingly, DS rats were sacrificed for gene chip analysis at 17 wk. All of the DS rats given a high-sodium diet showed signs of heart failure such as rapid and labored respiration and diffuse left ventricular hypokinesis on echocardiography at the time of sacrifice. Other DS rats were fed a low-salt diet (0.3% NaCl) as a control group.
###end p 30
###begin p 31
###xml 184 190 176 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 573 579 561 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 13 28 <span type="species:ncbi:10090">transgenic mice</span>
###xml 178 183 <span type="species:ncbi:10090">mouse</span>
###xml 580 595 <span type="species:ncbi:10090">transgenic mice</span>
We generated transgenic mice on a C57BL/6 background that expressed 12/15-LOX in cardiomyocytes under the control of the alpha-cardiac myosin heavy chain (alpha-MHC) promoter. A mouse Alox15 complementary DNA (cDNA) fragment (gift from C.D. Funk, University of Pennsylvania, Philadelphia, PA) fused with the HA tag was subcloned into the alpha-MHC promoter vector. The transgene was identified by genomic PCR with transgene-specific oligonucleotide primers (5'-CCACACCAGAAATGACAGAC-3' and 5'-GCGGGCAGGGAGACAAGTAG-3') and by Southern blot analysis. Two independent lines of Alox15 transgenic mice (lines 711 and 716) were obtained. The cardiac phenotype was similar in both lines of transgenic animals. WT littermates were used as the control for all experiments.
###end p 31
###begin p 32
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 189 206 189 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib36">Sano et al., 2007</xref>
###xml 17 21 <span type="species:ncbi:10090">mice</span>
###xml 229 233 <span type="species:ncbi:10090">mice</span>
###xml 249 253 <span type="species:ncbi:10090">mice</span>
Alox15-deficient mice on a C57BL/6 background were purchased from The Jackson Laboratory. WT littermates served as a control for all experiments. TAC was performed as described previously (Sano et al., 2007) on 10-11-wk-old male mice. Sham-operated mice underwent the same procedure without aorta constriction.
###end p 32
###begin p 33
###xml 140 164 140 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">Hayashidani et al., 2003</xref>
###xml 927 942 907 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">Ni et al., 2001</xref>
###xml 944 968 924 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">Hayashidani et al., 2003</xref>
###xml 37 42 <span type="species:ncbi:9606">human</span>
###xml 185 189 <span type="species:ncbi:10090">mice</span>
An expression vector encoding mutant human MCP-1 with deletion of N-terminal amino acids (7ND plasmid) was prepared as described elsewhere (Hayashidani et al., 2003). Under anesthesia, mice received an injection of 100 microg of either the empty vector or the 7ND plasmid in PBS into the bilateral tibial muscles using a 27-gauge needle fitted with a plastic collar that limited muscle penetration to approximately5 mm. Injection was performed every 2 wk from 10 wk until 48 wk of age. To increase the efficiency of gene transfection, 100 microl of the myotoxic agent bupivacaine (0.25% wt/vol) was injected into the muscles 3 d before transfection. Transfection of 7ND leads to an increase of mutant MCP-1 in the blood, as indicated by elevation of its plasma concentration after 14 d. The circulating mutant MCP-1 binds to the receptor for MCP-1 (chemokine receptor 2) on target cells and effectively blocks MCP-1 signaling (Ni et al., 2001; Hayashidani et al., 2003).
###end p 33
###begin title 34
Physiological and histological analysis.
###end title 34
###begin p 35
###xml 392 396 <span type="species:ncbi:10090">mice</span>
Echocardiography was performed with a Vevo 770 High Resolution Imaging System (Visual Sonics Inc.). To minimize variation of the data, the heart rate was approximately500-600 beats per minute when cardiac function was assessed. The peak systolic blood pressure was recorded by a photoelectric pulse devise (Blood Pressure Meter BP-98A; Softron Co. Ltd.) placed on the tails of unanesthetized mice. Under anesthesia, a micropressure transducer with an outer diameter of 0.42 mm (Samba 201 control unit and Samba Preclin 420 transducer; Samba Sensors AB) was introduced into the right carotid artery. Pressure signals were recorded with a MacLab 3.6/s data acquisition system (AD Instruments) at a sampling rate of 2,000 Hz. 4-microm frozen cross sections of the heart were fixed in 4% paraformaldehyde and subjected to Masson trichrome staining or immunohistochemistry for Mac3 (BD). Digital photographs were taken at 400x magnification of 25 random fields from each heart, and the number of Mac3-positive cells was counted in each field. The frozen cardiac cross sections were also stained with antibodies for 12/15-LOX (Cayman Chemical) and actinin (Sigma-Aldrich).
###end p 35
###begin title 36
DNA chip analysis.
###end title 36
###begin p 37
###xml 289 307 285 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">Ishii et al., 2000</xref>
###xml 65 69 <span type="species:ncbi:10116">rats</span>
10 microg of total RNA was extracted from the left ventricles of rats by the Li-Urea method and was used to synthesize biotin-labeled cRNA, which was then hybridized to a high-density oligonucleotide array (Gene Chip U34A array; Affymetrix) according to the previously published protocol (Ishii et al., 2000). The array contains probe sets for approximately8,800 genes and ESTs, which were selected from Build 34 of the UniGene Database (created from GenBank 107/dbEST 11/18/98). GeneChip 3.3 software (Affymetrix) was used to calculate the mean difference for each probe on the array, which showed the intensity of gene expression defined by Affymetrix using their algorithm. The mean difference has been shown to quantitatively reflect the abundance of a particular mRNA in a population. The data were deposited in GEO (GSM406556, GSM406557, and GSE16199).
###end p 37
###begin title 38
RNA analysis.
###end title 38
###begin p 39
###xml 415 421 411 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 544 550 540 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 675 681 671 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox12</italic>
###xml 42 46 <span type="species:ncbi:10090">mice</span>
###xml 540 543 <span type="species:ncbi:10116">Rat</span>
###xml 669 674 <span type="species:ncbi:10090">Mouse</span>
Total RNA was isolated from the hearts of mice with RNAZol-B (Molecular Research Center, Cincinnati, OH) and the ribonuclease protection assay (RiboQuant; BD) was performed according to the manufacturer's instructions. For Northern blot analysis, 30 microg of total RNA was separated on formaldehyde denaturing gel and transferred to a nylon membrane (GE Healthcare). Then the blot was hybridized with radiolabeled Alox15 cDNA probe using Quickhyb hybridization solution (Agilent Technologies) according to the manufacturer's instructions. Rat Alox15 cDNA fragment was a gift from T. Yoshimoto (Kanazawa University Graduate School of Medical Science, Kanazawa, Japan). Mouse Alox12 cDNA fragment was a gift from C.D. Funk. Real-time PCR was performed using a LightCycler (Roche) with the Taqman Universal Probe Library and the Light Cycler Master (Roche) according to the manufacturer's instructions.
###end p 39
###begin title 40
Western blot analysis.
###end title 40
###begin p 41
###xml 106 107 106 107 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 235 236 227 228 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 442 448 <span type="species:ncbi:9986">rabbit</span>
###xml 457 462 <span type="species:ncbi:10090">mouse</span>
###xml 496 507 <span type="species:ncbi:3704">horseradish</span>
###xml 974 979 <span type="species:ncbi:9606">human</span>
###xml 991 996 <span type="species:ncbi:10090">mouse</span>
Whole cell lysates were prepared in lysis buffer (10 mM Tris-HCl, pH 8, 140 mM NaCl, 5 mM EDTA, 0.025% NaN3, 1% Triton X-100, 1% deoxycholate, 0.1% SDS, 1 mM PMSF, 5 microg/ml leupeptin, 2 microg/ml aprotinin, 50 mM NaF, and 1 mM Na2VO3). 40-50 microg of the lysates were resolved by SDS-PAGE (PAGE). Then proteins were transferred to a nitrocellulose membrane (GE Healthcare), which was incubated with the primary antibody, followed by anti-rabbit or anti-mouse immunoglobulin G conjugated with horseradish peroxidase (Jackson ImmunoResearch Laboratories). Specific proteins were detected by using enhanced chemiluminescence (GE Healthcare). The primary antibodies used for Western blotting were as follows: anti-HA antibody (Santa Cruz Biotechnology, Inc.), anti-12/15-LOX antibody (Cayman Chemical), and anti-actin antibody (Sigma-Aldrich). ELISA was performed according to the manufacturer's instructions to examine the levels of 12(S)-HETE, 15(S)-HETE (Assay Designs), human MCP-1, and mouse MCP-1 (Invitrogen).
###end p 41
###begin title 42
Cell culture.
###end title 42
###begin p 43
###xml 194 211 194 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib36">Sano et al., 2007</xref>
###xml 9 20 <span type="species:ncbi:10116">Wistar rats</span>
###xml 151 155 <span type="species:ncbi:10116">rats</span>
###xml 214 219 <span type="species:ncbi:9606">Human</span>
Neonatal Wistar rats were purchased from Takasugi Experimental Animal Supply. Cardiomyocytes and cardiac fibroblasts were prepared from these neonatal rats and cultured as described previously (Sano et al., 2007). Human umbilical vein endothelial cells (BioWhittaker; Lonza) were cultured according to the manufacturer's instructions.
###end p 43
###begin title 44
Luciferase assay.
###end title 44
###begin p 45
###xml 149 156 141 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 507 526 495 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">Fujita et al., 1993</xref>
1 microg of the reporter gene plasmid was transfected into COS7 cells at 24 h before the luciferase assay. 0.1 microg of the control vector encoding Renilla luciferase was cotransfected as an internal control. The assay was performed using a dual luciferase reporter assay system (Promega) according to the manufacturer's instructions. p55-A2-Luc (the luciferase reporter gene containing the kappaB binding site) was a gift from T. Fujita (The Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan; Fujita et al., 1993).
###end p 45
###begin title 46
Statistical analysis.
###end title 46
###begin p 47
###xml 229 230 227 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Data are shown as the mean +/- SEM. Multiple group comparison was performed by one-way ANOVA, followed by Bonferroni's test for comparison of means. Comparisons between two groups were done with the two-tailed unpaired Student's t test or two-way ANOVA. In all analyses, P < 0.05 was considered statistically significant.
###end p 47
###begin title 48
Online supplemental material.
###end title 48
###begin p 49
###xml 16 22 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 204 210 204 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alox15</italic>
###xml 221 225 <span type="species:ncbi:10090">mice</span>
Fig. S1 depicts Alox15 transgenic animal data. Fig. S2 shows MCP-1 levels after treatment with 7ND. Fig. S3 shows a negative control of immunohistochemistry for 12/15-LOX. Fig. S4 shows blood pressure of Alox15-deficient mice. Table S1 summarizes the microarray data. Online supplemental material is available at .
###end p 49
###begin title 50
Supplementary Material
###end title 50
###begin title 51
[Supplemental Material]
###end title 51
###begin p 52
We thank Dr. C. Funk, Dr. T. Yoshimoto, and Dr. T. Fujita for reagents and E. Fujita, R. Kobayashi, Y. Ishiyama, and M. Ikeda for technical support.
###end p 52
###begin p 53
This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports, and Culture, and Health and Labor Sciences Research Grants (to I. Komuro), a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, grants from the Suzuken Memorial Foundation, the Japan Diabetes Foundation, the Ichiro Kanehara Foundation, the Tokyo Biochemical Research Foundation, and the Cell Science Research Foundation (to T. Minamino), grants from the Takeda Science Foundation and the Japan Foundation of Applied Enzymology (to T. Minamino and H. Toko), and Sakakibara Memorial research Grant from the Japan Research Promotion Society for Cardiovascular Disease (to H. Toko).
###end p 53
###begin p 54
The authors declare no competing financial interests.
###end p 54
###begin article-title 55
C-reactive protein in heart failure: prognostic value and the effect of valsartan.
###end article-title 55
###begin article-title 56
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice lacking 12/15-lipoxygenase have attenuated airway allergic inflammation and remodeling.
###end article-title 56
###begin article-title 57
###xml 76 79 <span type="species:ncbi:10116">rat</span>
Brain genomic response following hypoxia and re-oxygenation in the neonatal rat. Identification of genes that might contribute to hypoxia-induced ischemic tolerance.
###end article-title 57
###begin article-title 58
###xml 68 72 <span type="species:ncbi:10090">mice</span>
Resistance to type 1 diabetes induction in 12-lipoxygenase knockout mice.
###end article-title 58
###begin article-title 59
12/15-lipoxygenase regulates intercellular adhesion molecule-1 expression and monocyte adhesion to endothelium through activation of RhoA and nuclear factor-kappaB.
###end article-title 59
###begin article-title 60
###xml 98 102 <span type="species:ncbi:10090">mice</span>
12/15 lipoxygenase mediates monocyte adhesion to aortic endothelium in apolipoprotein E-deficient mice through activation of RhoA and NF-kappaB.
###end article-title 60
###begin article-title 61
Biomarkers in heart failure.
###end article-title 61
###begin article-title 62
###xml 116 122 <span type="species:ncbi:10090">murine</span>
cDNA cloning, expression, mutagenesis of C-terminal isoleucine, genomic structure, and chromosomal localizations of murine 12-lipoxygenases.
###end article-title 62
###begin article-title 63
Hypoxia-responsive transcription factors.
###end article-title 63
###begin article-title 64
###xml 88 92 <span type="species:ncbi:10090">mice</span>
Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice.
###end article-title 64
###begin article-title 65
###xml 118 122 <span type="species:ncbi:10090">mice</span>
Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice.
###end article-title 65
###begin article-title 66
Viral vector-mediated 12/15-lipoxygenase overexpression in vascular smooth muscle cells enhances inflammatory gene expression and migration.
###end article-title 66
###begin article-title 67
Molecular mechanisms mediating inflammation in vascular disease: special reference to monocyte chemoattractant protein-1.
###end article-title 67
###begin article-title 68
The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-kappa B p50 homodimers.
###end article-title 68
###begin article-title 69
###xml 104 112 <span type="species:ncbi:9606">patients</span>
Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative group on ACE inhibitor trials.
###end article-title 69
###begin article-title 70
###xml 86 90 <span type="species:ncbi:10090">mice</span>
12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice.
###end article-title 70
###begin article-title 71
Benefits of beta-blocker therapy for heart failure: weighing the evidence.
###end article-title 71
###begin article-title 72
###xml 119 123 <span type="species:ncbi:10090">mice</span>
Increased production of 12/15 lipoxygenase eicosanoids accelerates monocyte/endothelial interactions in diabetic db/db mice.
###end article-title 72
###begin article-title 73
Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction.
###end article-title 73
###begin article-title 74
Direct comparison of GeneChip and SAGE on the quantitative accuracy in transcript profiling analysis.
###end article-title 74
###begin article-title 75
Protecting against cerebrovascular injury: contributions of 12/15-lipoxygenase to edema formation after transient focal ischemia.
###end article-title 75
###begin article-title 76
###xml 64 70 <span type="species:ncbi:10090">murine</span>
Myocarditis induced by targeted expression of the MCP-1 gene in murine cardiac muscle.
###end article-title 76
###begin article-title 77
Phospholipase A2 enzymes.
###end article-title 77
###begin article-title 78
Inflammation and immune regulation by 12/15-lipoxygenases.
###end article-title 78
###begin article-title 79
Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation?
###end article-title 79
###begin article-title 80
Blockade of 12-lipoxygenase expression protects cortical neurons from apoptosis induced by beta-amyloid peptide.
###end article-title 80
###begin article-title 81
Braunwald's Heart Disease: a Textbook of Cardiovascular Medicine. 
###end article-title 81
###begin article-title 82
###xml 24 28 <span type="species:ncbi:10090">mice</span>
Nonobese diabetic (NOD) mice congenic for a targeted deletion of 12/15-lipoxygenase are protected from autoimmune diabetes.
###end article-title 82
###begin article-title 83
Major beta blocker mortality trials in chronic heart failure: a critical review.
###end article-title 83
###begin article-title 84
###xml 10 15 <span type="species:ncbi:9606">human</span>
Activated human monocytes oxidize low-density lipoprotein by a lipoxygenase-dependent pathway.
###end article-title 84
###begin article-title 85
12/15-Lipoxygenase activity increases the degradation of macrophage ATP-binding cassette transporter G1.
###end article-title 85
###begin article-title 86
Lipid inflammatory mediators in diabetic vascular disease.
###end article-title 86
###begin article-title 87
###xml 113 117 <span type="species:ncbi:10090">mice</span>
New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice.
###end article-title 87
###begin article-title 88
12/15-Lipoxygenase activity mediates inflammatory monocyte/endothelial interactions and atherosclerosis in vivo.
###end article-title 88
###begin article-title 89
Essential involvement of 12-lipoxygenase in regiospecific and stereospecific oxidation of low density lipoprotein by macrophages.
###end article-title 89
###begin article-title 90
p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload.
###end article-title 90
###begin article-title 91
Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent- and AIF-mediated cell death.
###end article-title 91
###begin article-title 92
The role of 12/15-lipoxygenase in the expression of interleukin-6 and tumor necrosis factor-alpha in macrophages.
###end article-title 92
###begin article-title 93
###xml 57 62 <span type="species:ncbi:10090">mouse</span>
Role of 12/15-lipoxygenase in the expression of MCP-1 in mouse macrophages.
###end article-title 93
###begin article-title 94
Arachidonate 12-lipoxygenase purified from porcine leukocytes by immunoaffinity chromatography and its reactivity with hydroperoxyeicosatetraenoic acids.
###end article-title 94
###begin article-title 95
###xml 124 130 <span type="species:ncbi:9986">rabbit</span>
Chronic hypoxia activates lung 15-lipoxygenase, which catalyzes production of 15-HETE and enhances constriction in neonatal rabbit pulmonary arteries.
###end article-title 95
###begin article-title 96
Low density lipoprotein receptor-related protein-mediated membrane translocation of 12/15-lipoxygenase is required for oxidation of low density lipoprotein by macrophages.
###end article-title 96
###begin p 97
Abbreviations used: cDNA, complementary DNA; FS, fractional shortening; HETE, hydroxy-eicosatetraenoic acids; LOX, lipoxygenase; LVDd, left ventricular diastolic dimension; MCP-1, monocyte chemoattractant protein 1; mRNA, messenger RNA; TAC, transverse aortic constriction.
###end p 97

